Share ownership Gilead Sciences, Inc.

GILD

US3755581036

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 18:51:18 12/12/2025 GMT			5-day change	1st Jan Change
120.40 ^USD	-2.28%		+0.09%	+31.35%

03:23pm	Arcus Biosciences, Inc. Provides Update on Phase 3 Star-221 Study and Concentrates Its R&D Investment on Cas Datifan and Emerging Inflammation and Immunology Portfolio	CI
02:28pm	Arcus, Gilead to Discontinue Phase 3 Trial of Potential Cancer Treatment -- Update	DJ

Share class: Gilead Sciences, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,246,000,000	1,244,733,708 ( 99.9 %)	0	99.9 %

Major shareholders: Gilead Sciences, Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 9.59 %	118,983,644	9.59 %	14 973 M $
BlackRock Advisors LLC 6.867 %	85,191,603	6.867 %	10 721 M $
Fidelity Management & Research Co. LLC 4.857 %	60,257,892	4.857 %	7 583 M $
STATE STREET CORPORATION 4.763 %	59,089,305	4.763 %	7 436 M $
Capital Research & Management Co. (World Investors) 3.642 %	45,179,931	3.642 %	5 685 M $
Dodge & Cox 2.429 %	30,133,131	2.429 %	3 792 M $
Capital Research & Management Co. (Global Investors) 2.419 %	30,014,046	2.419 %	3 777 M $
Geode Capital Management LLC 2.412 %	29,928,986	2.412 %	3 766 M $
Ishares (DE) InvAG mit Teilgesellschaftsvermogen 2.296 %	28,491,298	2.296 %	3 585 M $
T. Rowe Price International Ltd. 2.136 %	26,503,391	2.136 %	3 335 M $
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
BRAM - Bradesco Asset Management SA DTVM 0.000078 %	1,929	0.000078 %	120 812 $

Breakdown by shareholder type

Institutional	72.69%
Other	8.76%
State Street Corp.	4.76%
Schweizerische Nationalbank	0.29%
Sumitomo Mitsui Trust Group, Inc.	0.27%
Swedbank AB	0.2%
Governments	0.19%
Skandinaviska Enskilda Banken AB	0.18%
Manulife Financial Corp.	0.17%
SEI Investments Co.	0.14%
Danske Bank A/S	0.1%
Individuals	0.09%
Münchener Rückversicherungs-Gesellschaft AG	0.05%
Banco Bilbao Vizcaya Argentaria SA	0.05%
Fifth Third Bancorp	0.03%
ING Groep NV	0.02%
The Bank of Nova Scotia	0.02%
Migdal Insurance & Financial Holdings Ltd.	0.02%
Banque Cantonale Vaudoise	0.01%
First Horizon Corp. (Tennessee)	0.01%
BNP Paribas Fortis SA/NV	0.01%
Unknown	11.94%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	63.85%
United Kingdom	7.86%
Germany	2.82%
Canada	2.47%
Norway	1.74%
France	1.57%
Australia	1.22%
Switzerland	1.04%
Sweden	1.02%
Japan	0.78%
Denmark	0.59%
Netherlands	0.53%
Luxembourg	0.52%
Hong Kong	0.39%
South Korea	0.38%
Ireland	0.26%
Belgium	0.2%
Italy	0.12%
Austria	0.11%
China	0.11%
Finland	0.09%
Spain	0.09%
Individuals	0.09%
New Zealand	0.06%
Taiwan	0.04%
Czech Republic	0.03%
Israel	0.02%
Singapore	0.02%
India	0.01%
United Arab Emirates	0.01%
South Africa	0.01%
Slovenia	0.01%

Based on 1000 largest holdings

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (99.5%): for the treatment of HIV (68.5% of net sales), oncology diseases (11.5%), hepatitis B virus (10.6%), Ebola virus (6.3%) and other (3.1%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (0.5%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (71.6%), Europe (16.1%) and other (12.3%).

Employees

17,600

Sector

Pharmaceuticals

Calendar

12-14 - Ex-dividend day

More about the company